Changing lives
by saving sight.
A Bio-Inspired Therapeutic Platform offering a bright future for patients suffering from blinding ocular diseases.
Company Overview
Tarsier® Pharma is a late clinical-stage company dedicated to developing disruptive bio-inspired medical solutions for the treatment and cure of autoimmune and inflammatory ocular diseases. Benefiting from the combined knowledge and experience of some of the world's foremost experts on inflammatory ocular diseases, and after successful initial clinical trials, we believe our molecule-derived breakthrough approach has the potential to effectively control a range of autoimmune and inflammatory ocular diseases. Our proprietary platform, Dazdotuftide (TRS), re-engineers the immune system from within.
Press Releases
View all press releasesTarsier Pharma Appoints Ashley Kline as Chief Commercial Officer, expanding U.S. commercial leadership presence ahead of Phase 3 trial readout.
Read moreTarsier Pharma Receives FDA Agreement Under Special Protocol Assessment (SPA) for Tarsier-04 Phase 3 Trial in non-infectious uveitis.
Read moreTarsier Pharma Announces Phase 3 Clinical Trial Results from TRS4Vision in subjects with noninfectious anterior uveitis including uveitic glaucoma.
Read moreTarsier Pharma at a Glance
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla rutrum velit sed bibendum auctor.
Stock Information
July 15, 2025 · 4:15 PM ESTLatest Presentation
Explore our most recent investor presentation for key insights into our strategy, performance, and future outlook. This overview highlights our financials, growth initiatives, and the opportunities we're pursuing to deliver long-term shareholder value as we advance Dazdotuftide (TRS) through Phase 3 clinical trials and toward commercialization.
IR Contacts
Sign Up for Email Alerts
Stay connected and get the latest company news delivered to your inbox.